/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Kazia Therapeutics Ltd Share Price Today: Live Updates & Key Insights

Kazia Therapeutics Ltd share price today is $7.58, up -5.44%. The stock opened at $7.8 against the previous close of $7.91, with an intraday high of $7.8 and low of $7.4651.

Kazia Therapeutics Ltd Share Price Chart

style
pb-0

Kazia Therapeutics Ltd

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Kazia Therapeutics Ltd Share Price Performance

$7.58 -0.0544(-5.44%) KZIA at 23 Mar 2026 01:54 PM Biotechnology
Lowest Today 7.4651
Highest Today 7.8
Today’s Open 7.8
Prev. Close 7.91
52 Week High 17.40
52 Week Low 2.86
Day’s Range: Low 7.4651 High 7.8
52-Week Range: Low 2.86 High 17.40
1 day return -
1 Week return -6.18
1 month return +26.12
3 month return -23.35
6 month return +0.39
1 year return +697.89
3 year return +718.3
5 year return -35.21
10 year return -

Kazia Therapeutics Ltd Institutional Holdings

Alyeska Investment Group, L.P. 6.51

Stonepine Capital Management Llc 4.06

Bleichroeder LP 3.53

Exemplar Growth and Income Ser FD 1.95

Corsair Capital Management LLC 0.62

Westside Investment Management, Inc. 0.27

Barclays PLC 0.21

Rockefeller Capital Management L.P. 0.09

Engineers Gate Manager LP 0.09

UBS Group AG 0.03

Rhumbline Advisers 0.01

Citigroup Inc 0.01

GAMMA Investing LLC 0.00

Morgan Stanley - Brokerage Accounts 0.00

SRS Capital Advisors Inc 0.00

Fidelity Nasdaq Composite Index 0.00

Advisor Group Holdings, Inc. 0.00

Dauntless Investment Group, LLC 0.00

Hanson Mcclain Inc 0.00

Mccormack Advisors International 0.00

SBI Securities Co Ltd 0.00

Kazia Therapeutics Ltd Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Kazia Therapeutics Ltd Fundamentals

Market Cap 84.79 M

PB Ratio 3.0866

PE Ratio 0.0

Enterprise Value 82.02 M

Total Assets 6.06 M

Volume 61163

Kazia Therapeutics Ltd Company Financials

Annual Revenue FY25:42000 0.0M, FY24:2308000 2.3M, FY23:0 0.0M, FY22:25 0.0M, FY21:15183000 15.2M

Annual Profit FY25:42000 0.0M, FY24:2308000 2.3M, FY23:null 0.0M, FY22:25 0.0M, FY21:15183000 15.2M

Annual Net worth FY25:-20702000 -20.7M, FY24:-26778000 -26.8M, FY23:-20465180 -20.5M, FY22:-24647815 -24.6M, FY21:-8422000 -8.4M

Quarterly Revenue Q3/2025:19710 0.0M, Q4/2023:5 0.0M, Q3/2023:278 0.0M, Q2/2023:null 0.0M, Q1/2023:278 0.0M

Quarterly Profit Q3/2025:19710 0.0M, Q4/2023:5 0.0M, Q3/2023:278 0.0M, Q2/2023:null 0.0M, Q1/2023:278 0.0M

Quarterly Net worth Q3/2025:-9951035 -10.0M, Q4/2023:-8823513 -8.8M, Q3/2023:-3439576 -3.4M, Q2/2023:null 0.0M, Q1/2023:-3439576 -3.4M

About Kazia Therapeutics Ltd & investment objective

Company Information Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Organisation Biotechnology

Employees 6

Industry Biotechnology

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow

Kazia Therapeutics Ltd FAQs

What is the share price of Kazia Therapeutics Ltd today?

The current share price of Kazia Therapeutics Ltd is $7.58.

Can I buy Kazia Therapeutics Ltd shares in India?

Yes, Indian investors can buy Kazia Therapeutics Ltd shares by opening an international trading and demat account with Motilal Oswal.

How to buy Kazia Therapeutics Ltd shares in India?

You can easily invest in Kazia Therapeutics Ltd shares from India by:

Can I buy fractional shares of Kazia Therapeutics Ltd?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Kazia Therapeutics Ltd?

Kazia Therapeutics Ltd has a market cap of $84.79 M.

In which sector does Kazia Therapeutics Ltd belong?

Kazia Therapeutics Ltd operates in the Biotechnology sector.

What documents are required to invest in Kazia Therapeutics Ltd stocks?

To invest, you typically need:

What is the PE and PB ratio of Kazia Therapeutics Ltd?

The PE ratio of Kazia Therapeutics Ltd is N/A and the PB ratio is 3.09.